Serum IL-6/IL-10 ratio as a biomarker for the diagnosis and severity assessment of primary-open angle glaucoma

Ulhaq, Zulvikar Syambani; Soraya, Gita Vita; Hasan, Yuliono Trika Nur; Raras, Tri Yudani Mardining; Rachmawati, Ermin; Shodry, Syifaus; Kusuma, Muhammad A'raaf Sirojan

doi:10.1177/11206721211037133

Cited by 15 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-6 is also reduced with the treatment of 100 μmol/L ripasudil in our study. IL-6 is considered an important cytokine associated with the diagnosis and severity of POAG [ 40 , 41 ]. Therefore, reducing the secreted IL-8 and IL-6 levels can at least partly explain the benefit of ripasudil in the treatment of HTLV-1-infected hTM cells, further supporting the feasibility of using ripasudil for the relief of secondary glaucoma in HU.…”

Section: Discussionmentioning

confidence: 99%

Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Yang,

Kamoi,

Zong

et al. 2024

IJMS

View full text Add to dashboard Cite

Human T-cell leukemia virus type 1 (HTLV-1), a virus that affects 5–10 million people globally, causes several diseases, including adult T-cell leukemia-lymphoma and HTLV-1-associated uveitis (HU). HU is prevalent in Japan and often leads to secondary glaucoma, which is a serious complication. We investigated the efficacy of ripasudil, a Rho-associated coiled coil-forming protein kinase inhibitor, in alleviating changes in human trabecular meshwork cells (hTM cells) infected with HTLV-1. HTLV-1-infected hTM cells were modeled in vitro using MT-2 cells, followed by treatment with varying concentrations of ripasudil. We assessed changes in cell morphology, viability, and inflammatory cytokine levels, as well as NF-κB activation. The results showed that ripasudil treatment changed the cell morphology, reduced the distribution of F-actin and fibronectin, and decreased the levels of certain inflammatory cytokines, such as interleukin (IL)-6, IL-8, and IL-12. However, ripasudil did not significantly affect NF-κB activation or overall cell viability. These findings suggest that ripasudil has the potential to treat secondary glaucoma in patients with HU by modulating cytoskeletal organization and alleviating inflammation in HTLV-1-infected hTM cells. This study lays the foundation for further clinical studies exploring the effectiveness of ripasudil for the treatment of secondary glaucoma associated with HU.

show abstract

Section: Discussionmentioning

confidence: 99%

Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Yang,

Kamoi,

Zong

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Intense inflammatory staining in the optic nerve head of glaucoma eyes with an elevated proinflammatory BSF-2(IL-6) levels have been witnessed during histological examinations of the human retina [ 32 ]. Ulhaq et al, (2021) highlighted the importance of the BSF-2(IL-6) cytokine in the ocular inflammatory process in glaucoma and confirmed its utility as an early marker of injured retinal ganglion cells in glaucomatous animal models [ 11 ]. This is in line with our study findings.…”

Section: Discussionmentioning

confidence: 99%

Peripheral Blood B-Cell Subsets Frequency and Distribution and the BSF-2(IL-6) to CSIF:TGIF(IL-10) Ratio as Severity-Associated Signatures in Primary Open-Angle Glaucoma: A Case-Controlled Study

Mokhtar,

Elmadbouly,

Abo Elkheir

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Although primary open-angle glaucoma (POAG) is a major cause of blindness worldwide, patients’ immune response and its relation to the disease course have not been fully unraveled in terms of analyses of circulating B-cell subsets, as well as the association of these subsets with the severity of POAG clinical features. Subjects and Methods: Flow cytometry was used to determine B-cell subset frequencies from 30 POAG patients grouped by hierarchical cluster analysis or the mean deviation (MD) of the visual field (VF) and correlated with the patients’ clinical and pathological data, as well as with BSF-2(IL-6) and CSIF:TGIF(IL-10), which were quantified in peripheral blood samples of patients and controls by ELISA. Results: The total B-cell frequency was increased in the POAG group in comparison to the control group (n = 30). Frequencies of specific B-cell subsets, such as double-negative (DN) and naïve B-cell subsets, were increased in relation to the severity of the POAG disease. However, the unswitched memory B compartment subset decreased in the POAG group. Other non-typical B-cell subsets such as DN B cells also showed significant changes according to the POAG disease severity course. These differences allow us to identify POAG severity-associated inflammatory clusters in patients with specifically altered B-cell subsets. Finally, ocular parameters, biomarkers of inflammation, and other glaucoma-related or non-clinical scores exhibited correlations with some of these B-cell subpopulations. Conclusion: The severity of the POAG disease course is accompanied by changes in the B-cell subpopulation, namely, DN B cells. Furthermore, the existing relationship of the B-cell subset frequencies with the clinical and the inflammatory parameters BSF-2(IL-6), CSIF:TGIF(IL-10), and the BSF-2(IL-6) to CSIF:TGIF(IL-10) ratio suggests that these B lymphocyte cells could serve as potential molecular bio-markers for assessing POAG disease severity and/or progression.

show abstract

“… 46 At present, there are few studies on serum IL-6 and TNF-α levels in patients with PACG and there is no evidence to confirm that serum cytokine levels are directly correlated with the cytokine levels in the eyes. 47 This area of research requires further investigation with larger sample sizes.…”

Section: Discussionmentioning

confidence: 99%

The inflammatory cytokine profiles and ocular biometric characteristics of primary angle-closure glaucoma

Zeng

Jiang

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Objective To investigate the pathogenesis of primary angle-closure disease (PACG) by measuring the anatomical structures of the anterior and posterior segments of the eye and inflammatory markers in the peripheral blood. Methods This case–control study enrolled patients diagnosed with acute PACG (APACG) and chronic PACG (CPACG). It also enrolled control subjects without PACG. The anterior and posterior anatomical features were measured in all study participants. The levels of interleukin (IL)-6, tumour necrosis factor-α and the neutrophil-to-lymphocyte ratio (NLR) in the peripheral blood were measured. Results This study analysed a total of 99 eyes: 34 eyes from 34 patients with APACG, 28 eyes from 28 patients with CPACG and 37 eyes from 37 control patients with senile cataract. The axis length, corneal diameter, anterior chamber depth and anterior chamber volume were significantly smaller in the APACG and CPACG groups compared with the controls. The level of IL-6 in the peripheral blood of patients with PACG was significantly lower than that of the controls. The NLR in the peripheral blood of patients with PACG was significantly greater than that of the controls. Conclusions Changes in the ocular anatomy and some inflammatory markers might be involved in the pathogenesis of PACG.

show abstract

Serum IL-6/IL-10 ratio as a biomarker for the diagnosis and severity assessment of primary-open angle glaucoma

Cited by 15 publications

References 35 publications

Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Peripheral Blood B-Cell Subsets Frequency and Distribution and the BSF-2(IL-6) to CSIF:TGIF(IL-10) Ratio as Severity-Associated Signatures in Primary Open-Angle Glaucoma: A Case-Controlled Study

The inflammatory cytokine profiles and ocular biometric characteristics of primary angle-closure glaucoma

Contact Info

Product

Resources

About